H istochem istry in the Diagnosis o f M alignant M esotheliom a *

Size: px
Start display at page:

Download "H istochem istry in the Diagnosis o f M alignant M esotheliom a *"

Transcription

1 A n n a l s o f C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, No. 3 Copyright 1973, Institute for Clinical Science H istochem istry in the Diagnosis o f M alignant M esotheliom a * MILTON KANNERSTEIN, M.D., JACOB CHURG, M.D.,f AND DESMOND MAGNER, M.D.f Barnert Memorial Hospital Center, Paterson, NJ' Mt. Sinai School of Medicine, New York, NY ABSTRACT To improve the accuracy of diagnosis, 82 cases of malignant mesothelioma were studied for mucosubstance production by the periodic acid-schiff reaction after diastase digestion (DPAS) and the colloidal iron (C l) reaction before and after hyaluronidase. Twenty-six carcinomas of various origins, similarly treated, were compared. The tumors had been fixed and processed in routine fashion. The reactions were regarded as positive only when there was a significant number of stained cytoplasmic vacuoles and/or- stained secretion in tubular or glandular lumina or in spaces between epithelial cells. Scattered intracytoplasmic granules and positive material in the stroma or in mesenchymal tumors were not considered diagnostic. Approximately half of the mesotheliomas were Cl positive. All but two showed complete or partial removal of the C l positive secretion by hyaluronidase. Thus, almost half of the mesotheliomas were demonstrated to contain hyaluronic acid and almost 33 percent of these were shown to contain another type of acid mucosubstance as well. A parallelism appeared to exist between the degree of histologic differentiation and the production of hyaluronic acid. The production of neutral mucosubstance, as indicated by the DPAS, was not conclusively demonstrated in any mesothelioma. Each staining method showed a small number of equivocal reactions. Twelve of 26 carcinomas were DPAS and C l positive but hyaluronidase had no effect on the C l reaction. The necessity for the accurate diagnosis of malignant mesothelioma has assumed an added dimension because of its statistically significant association with exposure to as * This study is supported by American Cancer Society Grant No. E-489A. f Mt. Sinai School of Medicine, New York, NY $ University of Ottawa, Ottawa, Canada. bestos, and its apparent increased incidence in recent years. In addition to the usual desirability of precise tumor diagnosis for prognostic and therapeutic purposes, there are epidemiologic and legal considerations with mesothelioma. The difficulty of diagnosis of mesothelioma is compounded, above and beyond the 2 0 7

2 2 0 8 KAN N EBSTEIN, CHUBG AND MAGNER usual problem of anaplasia, by its many variations on an underlying theme of dimorphism. Although familiarity with the more frequently occurring histologic patterns increases the accuracy of diagnosis, a strong element of observer subjectivity remains.4 Therefore any method for developing more objective data is desirable. The production of the acid mucosubstance, hyaluronic acid, by many mesotheliomas has been studied by a number of investigators for possible diagnostic applicability.1' Their reports have not been conclusive as to actual utility with routinely fixed and processed tissue. The opportunity for special fixation and processing does not frequently present itself. Methods for demonstration of the absence of neutral mucosubstance, to assist in the exclusion of carcinoma, have been more widely applied in practice. In the course of studying a relatively large series of mesotheliomas, it has been attempted to evaluate the diagnostic usefulness of mucosubstance demonstration and this presentation is based on our experience. M ethods and M aterials This study was carried out on the level of routine diagnostic practicality. The material was fixed in formalin, with the exception of a few cases from Bouin s solution, and was embedded in paraffin in the usual manner. Staining techniques were limited to the periodic acid-schiff reaction (PAS), according to McManus,5 after exposure of the sections to diastase (DPAS) and the Hale colloidal iron stain as modified by Rinehart and Abul-Haj7 before (C l) and after the application of testicular hyaluronidase (H C I). The difference between the Cl and HCI preparations was taken as an indication of the extent to which any acid mucosubstance present consisted of hyaluronic acid. From a group of over 200 cases diagnosed as mesothelioma, pleural and peritoneal, material was available from 82 patients for the application of the methods mentioned.. All the cases used were of the epithelial, mixed or biphasic types. Since hyaluronic acid production by pure mesenchymal or sarcomatoid mesotheliomas does not assist in differentiation from sarcomas of other origins, no tumors of this type were included. Approximately 10 percent of the tumors in our total series were purely mesenchymal. In conformity with the principle of grading mesotheliomas by degrees of certainty of diagnosis, the cases were divided into three categories: (1 ) definite, (2) probable and (3) possible. The grading was based on the extent to which the tumor corresponded to well-defined histologic patterns as described by numerous authors including Churg, Rosen and Moolten,1 and Mccaughy.3 4 Those in the definite group had characteristic patterns while those in the probable group had some of the characteristic features although others were discrepant or lacking. The tumors in the possible group included atypical or nonspecific appearances which could not be assigned to another entity. The evaluation was based on hematoxylin and eosin sections without reference to the histochemical methods. The cases used were taken from each group in random fashion. For purposes of comparison, 26 carcinomas were similarly studied. Fourteen were adenocarcinomas, seven arising in the lung and one possibly coming from the lung. The others were solid carcinomas of which four were of pulmonary origin and one was possibly of such origin. The comparison of pulmonary carcinomas was believed relevant since a peripheral carcinoma spreading on the pleura is one of the more frequent imitators of mesothelioma. The other adenocarcinomas were from the gastrointestinal tract, breast and ovary.

3 H IST O C H E M IST R Y IN DIAGN OSIS O F M A LIG N A N T M E SO T H E L IO M A TABLE I H i s t o c h e m i c a l R e a c t i o n s o p 82 M e s o t h e l i o m a s a n d 26 C a r c i n o m a s Mesotheliomas Carcinoma Definite Probable Possible Total DPAS Positive DPAS Questionable Cl Positive 23 (77%) 13 (54%) 6 (21%) 42 (52%) 13 Cl Questionable R esults Presented in table I are data showing that 74 of 82 mesotheliomas showed no reactivity to DPAS. Eight cases presented a minimal or questionable reactivity. This was not the fine granularity described by Fisher and Hellstrom.2 The latter was present to a varying degree in a number of cases but could not be related diagnostically. No instance of unequivocal DPAS positivity was found. The DPAS was regarded as questionable when there was a distinct granular fuchsinophilic coloration of an occasional cell, and/or a rare vacuole rimmed by positively staining material or a small globule. In several cases, thinner than average sections, meticulously stained, dispelled the illusion of DPAS positivity. Brightly stained stroma insinuated between tumor cells occasionally simulated droplets of secretion. The importance of preliminary diastase digestion needs no emphasis. Many mesotheliomas have a copious glycogen content. A case was accepted as C l positive only where there was at least a moderate number of stained vacuoles. The rimming of cell borders, diffuse cytoplasmic staining or the presence of cytoplasmic granules were considered non-specific and an infrequent positive vacuole or globule as inconclusive. In some cases, the acid mucosubstance was present in coalescent vacuoles, in the lumina of the tubules seen in many mesotheliomas, in clefts between epithelial cells and in pools in those mesotheliomas with scattered epithelial cells and a myxoid intercellular substance. Staining of the connective tissue stroma was not regarded as diagnostically significant. If the Cl preparation was judged positive by the above criteria, it was compared with the HCI preparation and the extent of disappearance of the C l stained material determined. In table I are disclosed data that 52 percent of the entire series of 82 cases were Cl positive. The frequency of positivity ranged from 77 percent in the definite group through 54 percent of the probable to 21 percent of the possible. Although no attempt was made to quantitate the C l positivity in precise fashion, it was noted that all the strongly reacting cases, i.e., showing the largest amounts of stainable materials, were in the definite group. Six cases were inconclusive by the Cl method. Four of these were in the possible category, as compared with only 6 positives in this group. In table II, it can be seen that 40 of 42 positive cases showed a total or partial disappearance of C l positive material after hyaluronidase treatment. In 27 ( 64 percent) disappearance was complete. In two cases no change was detectable following hyaluronidase. These, added to 13 cases that showed incomplete removal, make a total of about 33 percent of the Cl positive cases that appear to contain an acid mucosubstance other than hyaluronic acid. The carcinomas that were Cl positive were DPAS positive with one exception. Cl

4 210 KANNERSTEIN, CHURG AND M AGNER staining was in most instances more extensive than the DPAS. Hyaluronidase had no effect on these. D iscussion Our experience indicates that histochemical methods, under routine conditions, are not the solution to all the problems of the diagnosis of mesothelioma. However, it would appear that they can be useful in many instances. In the definite cases where it is not necessary for diagnosis but where it is most likely to be positive, and most strongly positive, the demonstration of hyaluronic acid serves as confirmation. In those cases evaluated as merely possible, where the demonstration of hyaluronic acid would be most helpful, about 20 percent of cases are positive. In this category of uncertainty, a positive DPAS ( always accompanied, in our experience, by acid mucosubstance of hyaluronidase resistant character) was helpful in ruling out mesothelioma in favor of a carcinoma. It may be mentioned that some of the mesotheliomas that showed a questionable DPAS also showed acid mucosubstances that were only in part hyaluronic acid. The C l staining in these cases, especially when less marked, must be evaluated with caution. In the intermediate (probable) group, half the cases contained hyaluronic acid and here the information is certainly of help in diagnosis. The absence of demonstrable acid mucosubstance in almost half the total series may be attributed either to lack of its synthesis or dissolution in fixation and/or processing. In this study and discussion, terms mucosubstance and hyaluronic acid have been employed in a purely histochemical sense. Spicer, Horn and Leppi8 have referred to the lack of identity of the histochemical and biochemical characterization of mucopolysaccharides. What has been referred to as hyaluronic acid is the colloidal iron positive material sensitive to testicular hyaluronidase. Testicular hyaluronidase is known to be able also to remove certain chondroitin sulfates However, the definite characterization of the acid mucopolysaccharides of mesotheliomas was not the intent of this study. The identity of the DPAS positive material seen in small amounts in some mesotheliomas also was not established. It was not of such quantity or character in any of the cases as to resemble that seen in adenocarcinomas. This matter is discussed in the classic paper of Wagner, Munday and Harington.10 A final point of more general interest is the parallelism of the degrees of diagnostic certainty and the presence of hyaluronic acid. On a practical level, this would seem to substantiate the validity of the histologic criteria for the diagnosis. On a more theoretic level, this would seem to suggest a correlation between differentiation and the ability, qualitatively and quantitatively, to produce hyaluronic acid. TABLE II R e ACTION W1TH COLLOIDAL IKON" OF MESOTHELIOMAS AND CARCINOMAS AFTER HYALURONIDASE Mesothelioma Carcinoma Definite Probable Possible CI Positive (AMP Totally Removed HCIs AMP Diminished LAMP Unchanged

5 H ISTO CH EM ISTRY IN DIAGNOSIS O F MALIGNANT M ESOTH ELIOM A 211 References 1. C h u r g, J., R o s e n, S. H., a n d M o o l t e n, S.: Histologic characteristics of mesothelioma associated with asbestos. Ann. N.Y. Acad. Sci. 132: , F i s h e r, E. R. a n d H e l l s t r o m, H. R.: The periodic acid-schiff reaction as an aid in the identification of mesothelioma. Cancer 13: , I M c C a u g h e y, W. T. E.: Criteria for diagnosis of diffuse mesothelial tumors. Ann. N.Y. Acad. Sci. 132: , M c C a u g h e y, W. T. E. a n d O l d h a m, T. D.: Diffuse mesotheliomas: Morbid anatomical and histological diagnostic criteria, including, observer variation in histological diagnosis. Presented at the I.A.R.C. meeting of a Working Group to Assess the Biological Effects of Asbestos, Lyon, Oct. 2, M c M a n u s, J. F. A.: Histologic and histochemical uses of periodic acid. Stain Techn. 23:99 108, O e l s, H. C., H a r r i s o n, E. G., J r., C a r r, D. T., a n d B e n a t z, P. E.: Diffuse malignant mesothelioma of the pleura; a review of 3 7 cases. Chest 60: , R i n e h a r t, J. F. a n d A b u l - H a j, S. K.: An improved method for histological demonstration of acid mucopolysaccharides in tissues. Arch. Path , S p i c e r, S. S., H o r n, R. G., a n d L e p p i, T. J.: Histochemistry of connective tissue mucopolysaccharides. The Connective Tissue, B. M. Wagner and D. E. Smith, eds., Int. Acad, of Path. Monograph No. 7, Baltimore, William and Wilkins Co., p. 252, S p i c e r, S. S., C h a k r i n, L. W., W a r d e l l, J. R., Jr., a n d K e n d r i c k, W. : Histochemistry of mucopolysaccharides in the canine and human respiratory tract. Lab. Invest. 25: , W a g n e r, J. C., M u n d a y, D. E., a n d H a b i n g - t o n, J. S.: Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J. Path. Bact. 84:73-78, W i n s l o w, D. J. a n d T a y l o r, A. B.: Malignant peritoneal mesotheliomas. Cancer 13: , Z u g i b e, F. T.: Diagnostic Histochemistry. St. Louis, C. V. Mosby Co., p. 300, 1970.

The develpemental origin of mesothelium

The develpemental origin of mesothelium Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal

More information

Histologic Classification and Differential Diagnosis of Mesothelioma

Histologic Classification and Differential Diagnosis of Mesothelioma THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 173-180 Histologic Classification and Differential Diagnosis of Mesothelioma DARRYL CARTER, M.D. Department of Pathology, Yale University School of Medicine,

More information

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%

More information

Diagnostic Challenge. Department of Pathology,

Diagnostic Challenge. Department of Pathology, Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital

More information

Effusions: Mesothelioma and Metastatic Cancers

Effusions: Mesothelioma and Metastatic Cancers Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,

More information

Practical Effusion Cytology

Practical Effusion Cytology Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.

More information

Diseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours

Diseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains

More information

Cytopathology Case Presentation #8

Cytopathology Case Presentation #8 Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents

More information

Diagnosis of Mesothelioma Pitfalls and Practical Information

Diagnosis of Mesothelioma Pitfalls and Practical Information Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

Uses and Abuses of Pathology in Asbestos-exposed Populations

Uses and Abuses of Pathology in Asbestos-exposed Populations Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

More information

Comparison of tumour markers in malignant

Comparison of tumour markers in malignant Thorax 1985;40:91-95 Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma AR GIBBS, R HARACH, JC WAGNER, B JASANI From the Pathology Department, Welsh National School, Cardiff,

More information

Malignant mesothelioma of the pleura: relation

Malignant mesothelioma of the pleura: relation Thorax 1982;37:810-815 Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour MR LAW, MARGARET E HODSON, BE HEARD From the Cardiothoracic Institute and Brompton

More information

International Journal of Case Reports in Medicine

International Journal of Case Reports in Medicine International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon

More information

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

More information

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules Multiple Primary and Histology Site Specific Coding Rules KIDNEY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

How To Diagnose And Treat A Tumour In An Effusion

How To Diagnose And Treat A Tumour In An Effusion Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

Male. Female. Death rates from lung cancer in USA

Male. Female. Death rates from lung cancer in USA Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita

More information

Histology and Glycoconjugates Histochemistry in the Small and Large Intestinal Epithelium of the Malayan Pangolin, Manis javanica

Histology and Glycoconjugates Histochemistry in the Small and Large Intestinal Epithelium of the Malayan Pangolin, Manis javanica Kasetsart J. (Nat. Sci.) 41 : 186-191 (2007) Histology and Glycoconjugates Histochemistry in the Small and Large Intestinal Epithelium of the Malayan Pangolin, Manis javanica Apinun Suprasert*, Maleewan

More information

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* M. L. Newhouse TUC Centenary Institute of Occupational Health London School of Hygiene and Tropical Medicine London WCIE 7HT. England G. Berry

More information

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!

Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of

More information

Pleural and Pericardial fluids a one year analysis

Pleural and Pericardial fluids a one year analysis Pleural and Pericardial fluids a one year analysis Dr Olafsdottir Dr J Williams Department of Cytology, Llandough Hospital Contents Background Standards Aims/Questions Investigation group Results Conclusions

More information

Pathologist s Discussion of Plaintiffs Latest Theories

Pathologist s Discussion of Plaintiffs Latest Theories Pathologist s Discussion of Plaintiffs Latest Theories Mary Beth Beasley, MD Mt. Sinai Medical Center Annenberg Building 15th Floor Room 50 1468 Madison Avenue New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas

Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas International Urology and Nephrology 28 (1), pp. 73-77 (1996) Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas $. O. OZDAMAR,*

More information

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma

More information

How To Test For Cancer

How To Test For Cancer Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic

More information

Testimony of. Dr. James Crapo. April 26, 2005

Testimony of. Dr. James Crapo. April 26, 2005 Testimony of Dr. James Crapo April 26, 2005 Written Statement of Dr. James D. Crapo, Professor of Medicine, National Jewish Medical and Research Center and University of Colorado Health Sciences Center

More information

The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS

The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic

More information

Sir William Osler: Listen to the patient; the patient tells you everything.

Sir William Osler: Listen to the patient; the patient tells you everything. Sir William Osler: Listen to the patient; the patient tells you everything. Jean-Martin Charcot: The patient is a liar. Epidemiology of Mesothelioma Jeffrey H. Mandel, MD, MPH Division of Environmental

More information

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Exploring the Role of Vitamins in Achieving a Healthy Heart

Exploring the Role of Vitamins in Achieving a Healthy Heart Exploring the Role of Vitamins in Achieving a Healthy Heart There are many avenues you can take to keep your heart healthy. The first step you should take is to have a medical professional evaluate the

More information

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada Techniques,

More information

Rare Thoracic Tumours

Rare Thoracic Tumours Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC

More information

Malignant mesothelioma: incidence, asbestos

Malignant mesothelioma: incidence, asbestos British Journal of Industrial Medicine 1984;41: 39-45 Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology W E WRIGHT,' R P SHERWIN,2 ELIZABETH A DICKSON,' L BERNSTEIN,'

More information

Carcinosarcoma of the Ovary

Carcinosarcoma of the Ovary Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year old

More information

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion. Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case

More information

Malignant Mesothelioma in Urban Dogs

Malignant Mesothelioma in Urban Dogs Vet. Pathol. 20: 53 1-540 (I 983) Malignant Mesothelioma in Urban Dogs M. L. HARBISON and J. J. GODLESKI Department of Pathology, Harvard Medical School, Angel1 Memorial Animal Hospital, Brigham and Women

More information

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have

More information

Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.

Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system

More information

What is Mesothelioma?

What is Mesothelioma? What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Primary -Benign - Malignant Secondary

Primary -Benign - Malignant Secondary TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low

More information

Francine Lortie-Monette, MD, MSc, CSPQ, MBA Department of Epidemiology and Biostatistics University of Western Ontario 2003

Francine Lortie-Monette, MD, MSc, CSPQ, MBA Department of Epidemiology and Biostatistics University of Western Ontario 2003 ASBESTOS Francine Lortie-Monette, MD, MSc, CSPQ, MBA Department of Epidemiology and Biostatistics University of Western Ontario 2003 Asbestosis Asbestosis is a model for other dust diseases as well as

More information

Case of the. Month October, 2012

Case of the. Month October, 2012 Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900

More information

What is special about a stain, and why do we call some stains

What is special about a stain, and why do we call some stains Technical Articles Evolution of Use of Special Stains Alton D. Floyd, PhD Independent Consultant Edwardsburg, MI, USA What is special about a stain, and why do we call some stains special? We all think

More information

Neoplasms of the LUNG and PLEURA

Neoplasms of the LUNG and PLEURA Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:

More information

Post-Mortem Diagnosis of a Rare Biphasic Benign Multicystic Peritoneal Mesothelioma in an Indian Domestic Fowl (Gallus Domesticus)

Post-Mortem Diagnosis of a Rare Biphasic Benign Multicystic Peritoneal Mesothelioma in an Indian Domestic Fowl (Gallus Domesticus) ISSN 2320-5407 International Journal of Advanced Research (2014), Volume 2, Issue 7, 380-384 Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Post-Mortem

More information

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200 GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung

More information

Silent Time-Bomb, Mesothelioma

Silent Time-Bomb, Mesothelioma Silent Time-Bomb, Mesothelioma ーClinical Pathology Shotaro Maeda Tama-Nagayama Hospita,lNippon Medical School JAPAN Mesothelioma 1 General remarks 2 Pathology 3 Cytology 4 6 cases of the mesothelioma diagnosed

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063 PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi

More information

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014

More information

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron

More information

Ovarian tumors Ancillary methods

Ovarian tumors Ancillary methods Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of

More information

ALTHOUGH excellent accounts have been published in recent years of

ALTHOUGH excellent accounts have been published in recent years of THE EXFOLIATIVE CYTOLOGY OF DIFFUSE MALIGNANT MESOTHELIOMA BERNARD NAYLOR Department of Pathology, University of Michigan, Ann Arbor, Michigan, U.S.A. PLATE~ LXXXVI-XCI ALTHOUGH excellent accounts have

More information

Asbestos Disease: An Overview for Clinicians Asbestos Exposure

Asbestos Disease: An Overview for Clinicians Asbestos Exposure Asbestos Asbestos Disease: An Overview for Clinicians Asbestos Exposure Asbestos: A health hazard Exposure to asbestos was a major occupational health hazard in the United States. The first large-scale

More information

This factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.

This factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different. There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers

More information

Recommendations for the Reporting of Pleural Mesothelioma

Recommendations for the Reporting of Pleural Mesothelioma Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

More information

A. Pericardial smear. Examination of the pericardial aspirate can provide useful diagnostic information.

A. Pericardial smear. Examination of the pericardial aspirate can provide useful diagnostic information. 5. PERICARDIUM Heart is encased by the pericardium which has a visceral layer (a) covering the heart and the parietal layer (b). In normal states it is thin, transparent and the myocardium can be seen

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014 General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention

More information

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

3-F. Pathology of Mesothelioma

3-F. Pathology of Mesothelioma 3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which

More information

HEALTH CARE FOR EXPOSURE TO ASBESTOS. 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.

HEALTH CARE FOR EXPOSURE TO ASBESTOS. 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun. HEALTH CARE FOR PATIENTS WITH EXPOSURE TO ASBESTOS 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.ca HEALTH CARE FOR PATIENTS WITH EXPOSURE

More information

BIOBANK LPCE-NICE CHEST

BIOBANK LPCE-NICE CHEST BIOBANK LE-NIE HEST athologist :. BUTORI 12/09/2013 LE / HU Unit atient : N LH13-3603 N LB 13-0691 ID : RO A onsent : YES Age : 54 Diagnosis and staging : chronic pleuresia 5x1000µL BIOBANK LE-NIE HEST

More information

DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE

DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE Ryan Granger University of Rhode Island Cytotechnology program May 2, 2015 ASCT Annual Meeting Nashville, Tennessee DESMOPLASTIC SMALL ROUND

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

More than 2,500 people are diagnosed with mesothelioma in the UK each year.

More than 2,500 people are diagnosed with mesothelioma in the UK each year. This information is an extract from the booklet Understanding mesothelioma. You may find the full booklet helpful. We can send you a free copy see page 5. Contents Introduction Pleural mesothelioma Peritoneal

More information

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists

More information

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs Update of the scientific evidence on asbestos and cancer Kurt Straif, MD MPH PhD International Agency for Research on Cancer Lyon, France World Health Organisation Asturias, 17 March 2011 The IARC Monographs

More information

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,

More information

R-16: Chronic nonspecific cervisit

R-16: Chronic nonspecific cervisit R-16: Chronic nonspecific cervisit Ectoservikal squamous epithelium Endoservical columnar epithelium Dilated cystic endoservical glands lymphoplasmocytes R18:Squamous cell carcinoma insitu Neoplastic epithelium

More information

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT Written by: Karyn Varley MS, SCT(ASCP) The donating laboratory would like to remain anonymous. PATIENT HISTORY 28 year old female Lived

More information

Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics

Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information

More information

Malignant Mesothelioma Electron Microscopy

Malignant Mesothelioma Electron Microscopy 33 Malignant Mesothelioma Electron Microscopy Raoul Fresco In spite of recent advances in immunocytochemistry, electron microscopy continues to be the gold standard for the differential diagnosis of mesothelioma

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Laboratory of Experimental Pathology. National Cancer Institute. Bethesda. Md.

Laboratory of Experimental Pathology. National Cancer Institute. Bethesda. Md. Vet. Pathol. 16: 574-582 (1979) Mesotheliomas and Proliferative Lesions of the Testicular Mesothelium Produced in Fischer, Sprague-Dawley and Buffalo Rats by Methyl(acetoxymethy1)nitrosamine (DMN-OAc)

More information

CONTROL: For staining fungus; use a known positive such as those used for the GMS. Use skin, aorta or normal liver for positive PAS staining.

CONTROL: For staining fungus; use a known positive such as those used for the GMS. Use skin, aorta or normal liver for positive PAS staining. SURGICAL PATHOLOGY - HISTOLOGY Date: STAINING MANUAL - CARBOHYDRATES Page: 1 of 3 PAS - McMANNUS' PERIODIC ACID SCHIFF'S - GLYCOGEN PURPOSE: Glycogen is present in skin, liver, parathyroid glands and skeletal

More information

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from

More information

Pathology of lung cancer

Pathology of lung cancer Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu

More information

YOUR LUNG CANCER PATHOLOGY REPORT

YOUR LUNG CANCER PATHOLOGY REPORT UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

More information

Cardiac Masses and Tumors

Cardiac Masses and Tumors Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:

More information

Adler v 3M Co. 2013 NY Slip Op 32796(U) October 28, 2013 Sup Ct, New York County Docket Number: 190392/2012 Judge: Sherry Klein Heitler Cases posted

Adler v 3M Co. 2013 NY Slip Op 32796(U) October 28, 2013 Sup Ct, New York County Docket Number: 190392/2012 Judge: Sherry Klein Heitler Cases posted Adler v 3M Co. 2013 NY Slip Op 32796(U) October 28, 2013 Sup Ct, New York County Docket Number: 190392/2012 Judge: Sherry Klein Heitler Cases posted with a "30000" identifier, i.e., 2013 NY Slip Op 30001(U),

More information

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc.

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc. Scientific Update on Safe Use of Asbestos Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc.org When We Talk about Asbestos What Do We Mean? Anthophyllite

More information

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC. Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Understanding Pleural Mesothelioma

Understanding Pleural Mesothelioma Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to

More information

Diseases of peritoneum Lect. Al Qassim University, Faculty of Medicine Phase II Year III, CMD 332 Pathology Department 31-32

Diseases of peritoneum Lect. Al Qassim University, Faculty of Medicine Phase II Year III, CMD 332 Pathology Department 31-32 Diseases of peritoneum Lect Al Qassim University, Faculty of Medicine Phase II Year III, CMD 332 Pathology Department 31-32 Describe the etiology, pathogenesis and types of peritonitis Define ascites and

More information